Elias Evan D, Uhanova Julia, Minuk Gerald Y
Section of Hepatology, Department of Medicine, and.
Department of Pharmacology and Therapeutics, Rady College of Health Sciences, University of Manitoba, Winnipeg, Manitoba, Canada.
Can Liver J. 2020 Jun 4;3(2):177-187. doi: 10.3138/canlivj.2019-0006. eCollection 2020 Spring.
Recent data suggest intestinal immunity including immunoglobulin A (IgA) may contribute to the pathogenesis of alcohol-induced liver disease (ALD).
We documented serum IgA levels in ALD patients and determined whether those with elevated levels of IgA (E-IgA) had similar, more, or less advanced disease and different rates of progression than those with normal levels of IgA (N-IgA). Standard liver function tests (bilirubin, international normalized ratio [INR], and albumin), model for end-stage liver disease (MELD), and Fibrosis-4 (FIB-4) scores were used as indicators of disease severity.
From the study centre's clinical database, we identified 175 adult patients with ALD, 107 (61%) with E-IgA and 68 (39%) with N-IgA. Gender distribution and mean age of the two cohorts were similar. E-IgA patients had biochemical evidence of more advanced liver disease (higher serum bilirubin and INR and lower albumin levels) than N-IgA patients (s < .05). E-IgA patients also had significantly higher median MELD and FIB-4 scores (s < .01). A higher percentage of E-IgA patients had FIB-4 values in keeping with advanced fibrosis or cirrhosis (55% versus 28%, = .02). After mean follow-up periods of approximately 4 years, liver biochemistry and MELD and FIB-4 scores changed to similar extents in the two cohorts.
Serum IgA levels were increased in approximately 70% of ALD patients. Although these patients had biochemical and non-invasive indicators of more advanced disease, elevations in serum IgA levels do not predict disease progression; therefore, IgA is unlikely to be of importance in the pathogenesis of ALD.
近期数据表明,包括免疫球蛋白A(IgA)在内的肠道免疫可能在酒精性肝病(ALD)的发病机制中起作用。
我们记录了ALD患者的血清IgA水平,并确定与IgA水平正常(N-IgA)的患者相比,IgA水平升高(E-IgA)的患者是否患有相似、更严重或较不严重的疾病以及不同的疾病进展率。采用标准肝功能检查(胆红素、国际标准化比值[INR]和白蛋白)、终末期肝病模型(MELD)和纤维化-4(FIB-4)评分作为疾病严重程度的指标。
从研究中心的临床数据库中,我们确定了175例成年ALD患者,其中107例(61%)为E-IgA患者,68例(39%)为N-IgA患者。两个队列的性别分布和平均年龄相似。与N-IgA患者相比,E-IgA患者有更严重肝病的生化证据(血清胆红素和INR更高,白蛋白水平更低)(s<0.05)。E-IgA患者的MELD和FIB-4评分中位数也显著更高(s<0.01)。更高比例的E-IgA患者的FIB-4值符合晚期纤维化或肝硬化(55%对28%,P=0.02)。在平均随访约4年后,两个队列的肝脏生化指标、MELD和FIB-4评分变化程度相似。
约70%的ALD患者血清IgA水平升高。尽管这些患者有更严重疾病的生化和非侵入性指标,但血清IgA水平升高并不能预测疾病进展;因此,IgA在ALD发病机制中不太可能起重要作用。